Marcus & Millichap Q1 2026 slides: revenue beats forecast on CRE recovery

Marcus & Millichap posted Q1 2026 revenue of $171.5 million, beating consensus by 3.34% and rising 18.2% year over year, while adjusted EBITDA swung to $2.9 million from a loss of $8.7 million. Transaction activity improved materially, with total sales volume up 29.2% to $12.1 billion and financing fees up 48.1% to $26.8 million. Management sees continued recovery into Q2, supported by stronger CRE activity, a stable 10-year Treasury around 4%, and $334.5 million of liquidity despite $23.5 million in buybacks.

Analysis

MMI is a levered call option on a CRE rebound, but the hidden point is that the rebound is being led by the most transaction-efficient part of the market: smaller private-client deals and refinancing-driven flow, not trophy institutional trading. That matters because this mix supports revenue without requiring a full cyclical restoration in office or large-cap institutional markets; it also means the company can keep taking share as fragmented owners need execution, valuation guidance, and financing help. The financing segment strength is especially important: in a market where fewer assets are sold outright, fee pools migrate toward brokers that can monetize debt placement and recapitalizations.

The second-order winner is not just MMI but any lender or capital provider exposed to refi waves over the next 6-18 months. Roughly $1.4T of maturities creates a pipeline where even modestly lower transaction volumes can still support elevated fee activity because distress, extensions, and partial recapitalizations all generate work; the counterintuitive risk is that “lower-for-longer” transaction counts can still be revenue-positive for the best intermediaries. By contrast, office-heavy brokers and asset managers should underperform if this recovery remains bifurcated: the market can look healthy at the headline level while office remains structurally impaired and absorbs disproportionate management time with lower conversion rates.

The main reversal catalyst is not demand deterioration alone, but a repricing in rates or credit availability that freezes the refi pipeline before it monetizes. If the long end backs up or credit spreads widen, the near-term benefit to MMI’s financing franchise could roll off faster than brokerage volumes recover, making the stock vulnerable after a good quarter. The contrarian miss is that the market may be underestimating operating leverage: a modest further lift in transactions can translate into outsized EBITDA improvement because SG&A has already been pressured into a lower ratio, so incremental upside may come faster than consensus expects over the next 2-3 quarters.

Key Decisions for Investors

• Long MMI on a 3-6 month horizon; use dips post-earnings for entry. Risk/reward is attractive if transaction recovery persists because incremental volume should flow through at high operating leverage, but trim if the 10Y starts reaccelerating above prior range and freezes deal activity.
• Pair trade: long MMI / short CBRE or JLL for a 1-2 quarter relative-value expression. Thesis: MMI has cleaner exposure to private-client and refinancing flow, while larger-cap platforms are more exposed to slower institutional capital deployment; expect MMI to outperform if middle-market activity stays resilient.
• Buy MMI call spreads 3-6 months out rather than outright stock if you want convexity to a better-than-expected Q2/Q3 guide. This limits downside if macro volatility interrupts the CRE recovery while preserving upside from continued operating leverage.
• Avoid shorting MMI into the quarter unless rates reprice sharply higher. The balance sheet and buyback capacity reduce left-tail risk, and the stock could rerate quickly if financing revenue stays above trend.
• Watch CMBS/CRE credit proxies and regional banks with CRE exposure for confirmation; if refinancing stress rises while transactions hold, MMI can still outperform even as broader CRE sentiment weakens.